Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatocyte cell adhesion molecule 2 (HEPACAM2)
- Target
- HEPACAM2
- Molecular classification
- Immunoglobulin superfamily domain-containing protein, Cell adhesion molecule, Transmembrane glycoprotein, Other (Mitotic regulator)
01
Overview
Hepatocyte cell adhesion molecule 2 (HEPACAM2) is a transmembrane glycoprotein associated with the immunoglobulin superfamily. It is required during prometaphase for centrosome maturation, and its knockdown in cells results in prometaphase arrest, abnormal nuclear morphology, and apoptosis[1][2][5][7]. Poly(ADP-ribosylation) promotes its translocation to centrosomes, enhancing maturation and robust chromosome movement during mitosis[5][7]. HEPACAM2 mediates cell–cell and cell–matrix adhesion, contributing to tissue integrity and regulation of cell proliferation. Altered expression patterns are observed in multiple cancers and may act as biomarkers for disease progression or patient selection. Chromosomal deletions encompassing HEPACAM2 are implicated in hematological malignancies and neurodevelopmental syndromes[1][2][5][6].
- Other names
- MIKIMitotic kinetics regulatorUNQ305/PRO346FLJ38683RGD1305697HECA2_HUMAN
02
Biological functions
Cell adhesion (cell–cell and cell–matrix adhesion, structural integrity)Mitosis and mitotic kinetics (centrosome maturation, chromosome movement)Apoptosis (knockdown leads to abnormal nuclear morphology and cell death)Cell proliferation
03
Disease associations
Cancer (colorectal cancer, prostate cancer, hepatocellular carcinoma)Myelodysplastic syndromeMyeloid leukemiaNeurological/neurodevelopmental disorders (microcephaly, mental retardation, myoclonus dystonia)
04
Biomarkers
Expression levels are a prognostic biomarker in colorectal cancer (part of gene signatures)Expression pattern in hepatocellular carcinoma (diagnostic/prognostic significance)Potential biomarker in metastatic progression of canine mammary tumors
Beyond the preview
Go deeper on Hepatocyte cell adhesion molecule 2 (HEPACAM2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hepatocyte cell adhesion molecule 2 (HEPACAM2).